Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/172760
Title: Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement
Author: van Ingen, Jakko
Aksamit, Timothy
Andrejak, Claire
Böttger, Erik C.
Cambau, Emmanuelle
Daley, Charles L.
Griffith, David E.
Guglielmetti, Lorenzo
Holland, Steven M.
Huitt, Gwen A.
Koh, Won-Jung
Lange, Christoph
Leitman, Philip
Marras, Theodore K.
Morimoto, Kozo
Olivier, Kenneth N.
Santín Cerezales, Miguel
Stout, Jason E.
Thomson, Rachel
Tortoli, Enrico
Wallace, Richard J.
Winthrop, Kevin L.
Wagner, Dirk
Keywords: Malalties dels pulmons
Tuberculosi
Pulmonary diseases
Tuberculosis
Issue Date: 22-Mar-2018
Publisher: European Respiratory Society
Abstract: Nontuberculous mycobacterial pulmonary diseases (NTM-PD) are increasingly recognised as opportunistic infections of humans. These chronic pulmonary infections have two main presentations. The first is a fibro-cavitary disease, that occurs in patients with pre-existing pulmonary diseases, such as chronic obstructive pulmonary disease, bronchiectasis, previous tuberculosis or other structural lung disease. The second presentation is a nodular- bronchiectatic disease of primarily the lingula and middle lobe that tends to affect a middle- aged and elderly female population [1]. Treatment of NTM-PD requires long-term administration of complex multidrug therapies that are species-specific. Currently recommended regimens are supported by a very limited evidence base [2, 3]. The increasing incidence of NTM-PD has sparked increased interest in performing prospective randomised clinical trials [4]. One of the drawbacks of the existing case series and clinical trials is that they have applied different outcome measures [5]. This hampers meta-analyses, which are important in these still understudied infectious diseases. To enhance the quality and interpretability of the results of future trials and retrospective cohort studies, we aimed to formulate clear and broadly acceptable outcome definitions for NTM-PD treatment.
Note: Versió postprint del document publicat a: https://doi.org/10.1183/13993003.00170-2018
It is part of: European Respiratory Journal, 2018, vol. 51, num. 3, p. 1800170
URI: http://hdl.handle.net/2445/172760
Related resource: https://doi.org/10.1183/13993003.00170-2018
ISSN: 0903-1936
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
697675.pdf309.64 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.